Neoprobe Proves A Short Seller Wrong

by Web Master, Benzinga Editor
October 20, 2011 7:58 AM | 8 seconds read |
FDA acceptance of Neoprobe's application for a lymph-node mapping agent is a defeat for a hedge fund manager who waged a campaign to stop the review.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!